PDCD1 and esophageal squamous cell carcinoma: Three ESCC patients, with one HBV-negative patient (HBV–#1) and two HBV-positive patients (HBV+#1 and HBV+#2), were enrolled from the Southwest Hospital for exploring their response to anti-PD-1 therapy.